These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17048958)

  • 21. From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    De Corte BL
    J Med Chem; 2005 Mar; 48(6):1689-96. PubMed ID: 15771411
    [No Abstract]   [Full Text] [Related]  

  • 22. Molecular docking studies on tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepinone (TIBO) derivatives as HIV-1 NNRT inhibitors.
    Sapre NS; Gupta S; Pancholi N; Sapre N
    J Comput Aided Mol Des; 2008 Feb; 22(2):69-80. PubMed ID: 18163186
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
    Piscitelli F; Coluccia A; Brancale A; La Regina G; Sansone A; Giordano C; Balzarini J; Maga G; Zanoli S; Samuele A; Cirilli R; La Torre F; Lavecchia A; Novellino E; Silvestri R
    J Med Chem; 2009 Apr; 52(7):1922-34. PubMed ID: 19281225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Data mining using template-based molecular docking on tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepinone (TIBO) derivatives as HIV-1RT inhibitors.
    Sapre NS; Gupta S; Pancholi N; Sapre N
    J Mol Model; 2008 Nov; 14(11):1009-21. PubMed ID: 18642033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of the binding free energies of new TIBO-like HIV-1 reverse transcriptase inhibitors using a combination of PROFEC, PB/SA, CMC/MD, and free energy calculations.
    Eriksson MA; Pitera J; Kollman PA
    J Med Chem; 1999 Mar; 42(5):868-81. PubMed ID: 10072684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Theoretical studies on the molecular basis of HIV-1RT/NNRTIs interactions.
    Decha P; Intharathep P; Udommaneethanakit T; Sompornpisut P; Hannongbua S; Wolschann P; Parasuk V
    J Enzyme Inhib Med Chem; 2011 Feb; 26(1):29-36. PubMed ID: 20583854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase.
    Ren J; Stammers DK
    Virus Res; 2008 Jun; 134(1-2):157-70. PubMed ID: 18313784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A group center overlap based approach for "3D QSAR" studies on TIBO derivatives.
    Sapre NS; Gupta S; Pancholi N; Sapre N
    J Comput Chem; 2009 Apr; 30(6):922-33. PubMed ID: 18785154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modelling the binding of HIV-reverse transcriptase and nevirapine: an assessment of quantum mechanical and force field approaches and predictions of the effect of mutations on binding.
    Raju RK; Burton NA; Hillier IH
    Phys Chem Chem Phys; 2010 Jul; 12(26):7117-25. PubMed ID: 20480085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative structure-activity relationship studies on anti-HIV-1 TIBO derivatives as inhibitors of viral reverse transcriptase.
    Gupta SP; Garg R
    J Enzyme Inhib; 1996 Aug; 11(1):23-32. PubMed ID: 9204393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
    Sweeney ZK; Harris SF; Arora SF; Javanbakht H; Li Y; Fretland J; Davidson JP; Billedeau JR; Gleason SK; Hirschfeld D; Kennedy-Smith JJ; Mirzadegan T; Roetz R; Smith M; Sperry S; Suh JM; Wu J; Tsing S; Villaseñor AG; Paul A; Su G; Heilek G; Hang JQ; Zhou AS; Jernelius JA; Zhang FJ; Klumpp K
    J Med Chem; 2008 Dec; 51(23):7449-58. PubMed ID: 19007201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Substituted tetrahydroquinolines as potent allosteric inhibitors of reverse transcriptase and its key mutants.
    Su DS; Lim JJ; Tinney E; Wan BL; Young MB; Anderson KD; Rudd D; Munshi V; Bahnck C; Felock PJ; Lu M; Lai MT; Touch S; Moyer G; Distefano DJ; Flynn JA; Liang Y; Sanchez R; Prasad S; Yan Y; Perlow-Poehnelt R; Torrent M; Miller M; Vacca JP; Williams TM; Anthony NJ
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5119-23. PubMed ID: 19631528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.
    Butini S; Brindisi M; Cosconati S; Marinelli L; Borrelli G; Coccone SS; Ramunno A; Campiani G; Novellino E; Zanoli S; Samuele A; Giorgi G; Bergamini A; Di Mattia M; Lalli S; Galletti B; Gemma S; Maga G
    J Med Chem; 2009 Feb; 52(4):1224-8. PubMed ID: 19170521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Binding energy analysis for wild-type and Y181C mutant HIV-1 RT/8-Cl TIBO complex structures: quantum chemical calculations based on the ONIOM method.
    Saen-oon S; Kuno M; Hannongbua S
    Proteins; 2005 Dec; 61(4):859-69. PubMed ID: 16245320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
    Tambuyzer L; Azijn H; Rimsky LT; Vingerhoets J; Lecocq P; Kraus G; Picchio G; de Béthune MP
    Antivir Ther; 2009; 14(1):103-9. PubMed ID: 19320243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Revealing interaction mode between HIV-1 reverse transcriptase and diaryltriazine analog inhibitor.
    Li Z; Han J; Chen HF
    Chem Biol Drug Des; 2008 Nov; 72(5):350-9. PubMed ID: 19012571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of the protonation state in the interaction of an HIV-1 reverse transcriptase (RT) amino acid, Lys101, and a non nucleoside RT inhibitor, GW420867X.
    Galembeck SE; Bickelhaupt FM; Fonseca Guerra C; Galembeck E
    J Mol Model; 2014 Jul; 20(7):2332. PubMed ID: 24965933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis, biological evaluation, and molecular modeling studies of TIBO-like cyclic sulfones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Di Santo R; Costi R; Artico M; Ragno R; Lavecchia A; Novellino E; Gavuzzo E; La Torre F; Cirilli R; Cancio R; Maga G
    ChemMedChem; 2006 Jan; 1(1):82-95. PubMed ID: 16892340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Support vector machines: development of QSAR models for predicting anti-HIV-1 activity of TIBO derivatives.
    Darnag R; Mostapha Mazouz EL; Schmitzer A; Villemin D; Jarid A; Cherqaoui D
    Eur J Med Chem; 2010 Apr; 45(4):1590-7. PubMed ID: 20110136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative structure-activity relationships and comparative molecular field analysis of TIBO derivatised HIV-1 reverse transcriptase inhibitors.
    Hannongbua S; Pungpo P; Limtrakul J; Wolschann P
    J Comput Aided Mol Des; 1999 Nov; 13(6):563-77. PubMed ID: 10584215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.